CXCL10 and Bartsocas-Papas syndrome 1: This study revealed that using a cluster of urinary biomarkers such as TNF-α ≥ CQ3 (0.95 pg/mL) or 8-OHdG ≥ CQ3 (22.34 pg/mL) and 8-isoprostane ≥ CQ2 (13.35 pg/mL) can identify patients with IC/BPS from the study cohort and that adding the urinary IP-10 ≥ CQ3 (19.94 pg/mL) can identify HIC from the IC/BPS cohort.